Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) [Phase 3]

View source ↗

Summary

Phase 3 study to evaluate crizanlizumab (5 mg/kg) vs placebo in adolescents and adults with sickle cell disease and frequent vaso-occlusive crises; recruitment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ADAKVEO (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 3 | Status: RECRUITING